SSRI CHINA news

Staffs from SSRI CHINA and SSRI headquarters attended the 8th CphMRA (China Pharmaceutical Market Research Association) conference held during October 23^rd-25^th in Nanjing. There was an attendance of around 300 people, and according to the organizers, around 2/3 of the attendees were from pharmaceutical companies. SSRI CHINA had a booth, participated in a poster session, and Jane Zhang did a presentation about diseases with high unmet needs in China based on the PatientsMap CN 2018 data.

Jane’s presentation explained that hypertension, diabetes, hyperlipidemia and COPD are the top diseases in which Chinese physicians wish for new treatments overall, suggesting that lifestyle diseases are considered as a major social problem in China.  However, when looking at more specific conditions that are treated by more specialized doctors, hematologic malignancies, neuro-muscular disorders and psychiatric conditions are considered as diseases with very high unmet needs, suggesting that for specific conditions, there is a high unmet need for innovative and/or orphan drugs, which is similar to that of Western countries.  Jane’s presentation received a third-place award out of all 33 presentations.

About PatientsMap

PatientsMap is a physician survey database product which uncovers the types of diseases that various specialists see, and the monthly patient volume for each disease. The database product is available for 4 countries; Japan, USA, UK and China. PatientsMap China 2018 data is collected from over 10,000 physicians, covering approximately 350 diseases/conditions.

For more details, please refer to the PatientsMap page in our website (above tab); /china/e/patientsmap

SSRI and SSRI CHINA attended the Intellus Worldwide Summit in Philadelphia from May 19-21. We had a booth (as always) and we had many gifts (as always). Those macaron shaped post it notes look nice...

Chiharu from HQ and Jane from CN

Previously (in July 2018), we shared the top 15 pharmaceutical companies with the highest sales rep visitation rates in China according to the PatientsMap 2018 CN data (table 2).

This time, we are sharing the top 5 pharmaceutical companies with the highest sales rep visitation rates in specific clinical departments, in particular, clinical departments with relatively strong domestic company presence.

Table 1 shows the top 5 companies with highest sales rep visitation rates in 10 clinical departments (e.g. 48.7% of 476 gastroenterologists met a sales rep from AstraZeneca in the past month). While major global companies generally occupy the top 3 spots, there are also some domestic companies such as Chia-Tai Tianqing (CTTQ) Pharmaceutical and Jiangsu Hengrui Medicine that rank highly in some clinical departments. In particular, domestic companies occupy the top 3 stops in the anesthesiology department.

In terms of domestic companies, Hengrui ranks second in radiology and anesthesiology departments and third in RA/immunology and oncology departments; and CTTQ ranks second in gastroenterology and infectious diseases departments and third in hematology department.

The rankings for all 32 clinical departments are available in the PatientsMap 2018 CN database.

Table 1. Top 5 sales rep visits (10 departments)

Table 2. PatientsMap 2018 CN – top 15 sales rep visits (n=10,285) from July 2018 news release

It's the year of the pig -